FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009952106> ?p ?o ?g. }

• W2009952106 endingPage "327" @default.
• W2009952106 startingPage "320" @default.
• W2009952106 abstract "4-Anilinoquinazolines (e.g. Iressa and Glivec) are a class of epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors widely used to treat non-small cell lung cancer and other tumors. However, low clinical response rate, resistance, and host toxicity of currently available EGFR-TK inhibitors prompt the development of second generation of TK inhibitors with improved efficacy, selectivity, and less resistance. CH330331 is a recently synthesized novel 4-anilinoquinazoline analog with confirmed anticancer activity in vitro and in vivo. To predict its oral pharmacokinetic behavior and transport nature in the intestine before entering clinical trials, we have developed and validated a high performance liquid chromatographic (HPLC) method for the determination of CH330331 in Caco-2 (a human colon cancer cell line) monolayers. The developed HPLC method was sensitive and reliable, with acceptable accuracy (90–110% of nominal values) and precision (intra- and inter-assay R.S.D. < 10%). The total running time was within 10 min, with acceptable separation of the target analytes. The lower limit of quantitation (LLOQ) value for CH330331 was 200 ng/ml when an aliquot of 100 μl sample was injected onto the HPLC. The validated HPLC method was applied to characterize the epithelial transport of CH330331 in Caco-2 monolayers. The transport of CH330331 across the Caco-2 monolayers from the apical to basolateral side was 8- to 10-fold higher than that from the basolateral to apical side. Co-incubation of sodium azide or MK-571, but not verapamil, significantly inhibited the apical to basolateral transport of CH330331. These findings provide initial evidence that the intestinal absorption of CH330331 is mediated by an active mechanism. Further studies are required to explore the interaction of CH330331 with ATP-binding cassette transporters and the possible influence on its pharmacokinetics and pharmacodynamics." @default.
• W2009952106 created "2016-06-24" @default.
• W2009952106 creator A5019107660 @default.
• W2009952106 creator A5022693074 @default.
• W2009952106 creator A5027649946 @default.
• W2009952106 creator A5041336256 @default.
• W2009952106 creator A5043273438 @default.
• W2009952106 creator A5073101602 @default.
• W2009952106 creator A5073319973 @default.
• W2009952106 creator A5075176020 @default.
• W2009952106 creator A5077507968 @default.
• W2009952106 creator A5084461358 @default.
• W2009952106 date "2007-07-01" @default.
• W2009952106 modified "2023-10-16" @default.
• W2009952106 title "Determination of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase, in human Caco-2 monolayers by high performance liquid chromatography with ultraviolet detection: Application to a trans-epithelial transport study" @default.
• W2009952106 cites W1964005903 @default.
• W2009952106 cites W1977340600 @default.
• W2009952106 cites W1978750894 @default.
• W2009952106 cites W1984226397 @default.
• W2009952106 cites W1984246155 @default.
• W2009952106 cites W2016493446 @default.
• W2009952106 cites W2016710415 @default.
• W2009952106 cites W2018388482 @default.
• W2009952106 cites W2028273867 @default.
• W2009952106 cites W2034515307 @default.
• W2009952106 cites W2045156702 @default.
• W2009952106 cites W2047226165 @default.
• W2009952106 cites W2058839845 @default.
• W2009952106 cites W2063851889 @default.
• W2009952106 cites W2074887652 @default.
• W2009952106 cites W2084375116 @default.
• W2009952106 cites W2088597803 @default.
• W2009952106 cites W2093423704 @default.
• W2009952106 cites W2094220461 @default.
• W2009952106 cites W2099895086 @default.
• W2009952106 cites W2110012018 @default.
• W2009952106 cites W2114918609 @default.
• W2009952106 cites W2135117965 @default.
• W2009952106 cites W2141125468 @default.
• W2009952106 cites W2147930289 @default.
• W2009952106 cites W2161541244 @default.
• W2009952106 cites W2188149910 @default.
• W2009952106 cites W4256555506 @default.
• W2009952106 cites W64286793 @default.
• W2009952106 doi "https://doi.org/10.1016/j.jchromb.2007.03.052" @default.
• W2009952106 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17467348" @default.
• W2009952106 hasPublicationYear "2007" @default.
• W2009952106 type Work @default.
• W2009952106 sameAs 2009952106 @default.
• W2009952106 citedByCount "6" @default.
• W2009952106 countsByYear W20099521062016 @default.
• W2009952106 crossrefType "journal-article" @default.
• W2009952106 hasAuthorship W2009952106A5019107660 @default.
• W2009952106 hasAuthorship W2009952106A5022693074 @default.
• W2009952106 hasAuthorship W2009952106A5027649946 @default.
• W2009952106 hasAuthorship W2009952106A5041336256 @default.
• W2009952106 hasAuthorship W2009952106A5043273438 @default.
• W2009952106 hasAuthorship W2009952106A5073101602 @default.
• W2009952106 hasAuthorship W2009952106A5073319973 @default.
• W2009952106 hasAuthorship W2009952106A5075176020 @default.
• W2009952106 hasAuthorship W2009952106A5077507968 @default.
• W2009952106 hasAuthorship W2009952106A5084461358 @default.
• W2009952106 hasConcept C10390740 @default.
• W2009952106 hasConcept C112705442 @default.
• W2009952106 hasConcept C150903083 @default.
• W2009952106 hasConcept C170493617 @default.
• W2009952106 hasConcept C179998833 @default.
• W2009952106 hasConcept C185592680 @default.
• W2009952106 hasConcept C193176779 @default.
• W2009952106 hasConcept C202751555 @default.
• W2009952106 hasConcept C207001950 @default.
• W2009952106 hasConcept C2779438470 @default.
• W2009952106 hasConcept C2781417787 @default.
• W2009952106 hasConcept C42362537 @default.
• W2009952106 hasConcept C43617362 @default.
• W2009952106 hasConcept C55493867 @default.
• W2009952106 hasConcept C71924100 @default.
• W2009952106 hasConcept C86803240 @default.
• W2009952106 hasConcept C98274493 @default.
• W2009952106 hasConceptScore W2009952106C10390740 @default.
• W2009952106 hasConceptScore W2009952106C112705442 @default.
• W2009952106 hasConceptScore W2009952106C150903083 @default.
• W2009952106 hasConceptScore W2009952106C170493617 @default.
• W2009952106 hasConceptScore W2009952106C179998833 @default.
• W2009952106 hasConceptScore W2009952106C185592680 @default.
• W2009952106 hasConceptScore W2009952106C193176779 @default.
• W2009952106 hasConceptScore W2009952106C202751555 @default.
• W2009952106 hasConceptScore W2009952106C207001950 @default.
• W2009952106 hasConceptScore W2009952106C2779438470 @default.
• W2009952106 hasConceptScore W2009952106C2781417787 @default.
• W2009952106 hasConceptScore W2009952106C42362537 @default.
• W2009952106 hasConceptScore W2009952106C43617362 @default.
• W2009952106 hasConceptScore W2009952106C55493867 @default.
• W2009952106 hasConceptScore W2009952106C71924100 @default.
• W2009952106 hasConceptScore W2009952106C86803240 @default.
• W2009952106 hasConceptScore W2009952106C98274493 @default.
• W2009952106 hasIssue "1-2" @default.
• W2009952106 hasLocation W20099521061 @default.

• next